[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600283":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":28,"locations":36,"responsibleParty":118,"collaborators":120,"id":124,"slug":125,"hasResults":126,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":126,"sex":132,"minAge":133,"maxAge":19,"enrollmentInfo":134,"targetDuration":19,"studyType":137,"phases":138,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":148,"whyStopped":19,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},{"fullName":5,"class":6},"Metanoic Health Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Artesunate","EXPERIMENTAL","200mg oral tablets once daily for 14 days, with 7 days break for 3 cycles.",[13],"Drug: Artesunate",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients with HPV positive CIN2\u002F3 will receive 3 cycles of oral artesunate 200mg OD prior to standard of care therapeutic LLETZ. Each 21 day treatment cycle will comprise oral artesunate 200mg OD for 14 days followed by a 7 day treatment break.",[9],null,[21,25],{"name":22,"affiliation":23,"role":24},"Professor Sanjeev Krishna, FRCP, ScD","Centre of Diagnostics and Therapeutics","STUDY_CHAIR",{"name":26,"affiliation":23,"role":27},"Dr Yolanda Augustin","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":19,"email":33},"Professor Sanjeev Krishna, FRCP,ScD","CONTACT","+442087250446","skrishna@cadt.org.uk",{"name":26,"role":31,"phone":19,"phoneExt":19,"email":35},"yaugustin@cadt.org.uk",[37,58,70,88,101],{"facility":38,"status":19,"city":39,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Pusat Perubatan Universiti Malaya","Kuala Lumpur","59100","Malaysia","MY",{"type":44,"coordinates":45},"Point",[46,47],101.68653,3.1412,{"lat":47,"lon":46},[50,54,57],{"name":51,"role":31,"phone":52,"phoneExt":19,"email":53},"Prof Woo Yin Ling","+60172152964","ylwoo@ummc.edu.my",{"name":55,"role":31,"phone":19,"phoneExt":19,"email":56},"Milisha Magesvaran","milisha.koh@ummc.edu.my",{"name":51,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":59,"status":19,"city":60,"state":39,"zip":61,"country":41,"countryCode":42,"cosmosGeoPoint":19,"geoPoint":19,"contacts":62},"Institut Kanser Negara","Putrajaya","62250",[63,66,69],{"name":64,"role":31,"phone":52,"phoneExt":19,"email":65},"Dr Jamil Omar","drjamil@nci.gov.my",{"name":67,"role":31,"phone":19,"phoneExt":19,"email":68},"Erda Syerena Binti Rosli","erdasyerena@clinicalresearch.my",{"name":64,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":71,"status":19,"city":72,"state":73,"zip":74,"country":41,"countryCode":42,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Hospital Umum Sarawak","Kuching","Sarawak","93586",{"type":44,"coordinates":76},[77,78],110.33333,1.55,{"lat":78,"lon":77},[81,84,87],{"name":82,"role":31,"phone":52,"phoneExt":19,"email":83},"Dr Kervindran Mohansundram","kervindran@gmail.com",{"name":85,"role":31,"phone":19,"phoneExt":19,"email":86},"Azian Nadiah Faisal","azian@clinicalresearch.my",{"name":82,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":89,"status":19,"city":90,"state":91,"zip":92,"country":41,"countryCode":42,"cosmosGeoPoint":19,"geoPoint":19,"contacts":93},"Hospital Ampang","Ampang","Selangor","68000",[94,97,100],{"name":95,"role":31,"phone":52,"phoneExt":19,"email":96},"Dr Yong Chee Meng","cmy2050@hotmail.com",{"name":98,"role":31,"phone":19,"phoneExt":19,"email":99},"Nur Syakirah Mohamed Elias","nur.syakirah@clinicalresearch.my",{"name":95,"role":27,"phone":19,"phoneExt":19,"email":19},{"facility":102,"status":19,"city":103,"state":91,"zip":104,"country":41,"countryCode":42,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Hospital Selayang","Batu Caves","68100",{"type":44,"coordinates":106},[107,108],101.682,3.238,{"lat":108,"lon":107},[111,114,117],{"name":112,"role":31,"phone":52,"phoneExt":19,"email":113},"Dr Vicknesh Visvalingam","vicknesh.visvalingam@gmail.com",{"name":115,"role":31,"phone":19,"phoneExt":19,"email":116},"Azizah Nazri","azizah@clinicalresearch.my",{"name":112,"role":27,"phone":19,"phoneExt":19,"email":19},{"type":119,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[121],{"name":122,"class":123},"Clinical Research Malaysia","UNKNOWN","100600283","phase-2-safety-and-efficacy-of-oral-artesunate-for-pre-cervical-cancer-100600283",false,"NCT07095478","Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer","Phase II Single Arm, Open Label Study of Artesunate for the Treatment of Human Papilloma Virus Positive High Grade Cervical Intraepithelial Neoplasia (CIN2\u002F3)","NeoART-CIN","Inclusion Criteria:\n\n* Aged 18 or over\n* Histologically proven HPV positive cervical CIN2\u002F3\n* WHO performance status 0-2\n* Adequate full blood count:\n* White Cell Count (WCC) \\>3.0 x 109 \u002Fl;\n* Platelets \\>100 x 109\u002Fl;\n* Haemoglobin (Hb) \\>80g\u002FL\n* Adequate renal function:\n* Glomerular Filtration Rate \\>30ml\u002Fmin\n* Adequate hepatobiliary function:\n* Total bilirubin \\\u003C 3 x Upper limit normal\n* Female participants of child bearing potential must have a negative pregnancy test \\\u003C 72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved contraceptive precautions for up to 6 weeks after the last dose of study treatment intervention\n* Patient able and willing to provide written, informed consent for the study\n\nExclusion Criteria:\n\n* • Contraindication to the use of artesunate due to hypersensitivity\n\n  * Pregnancy or lactation\n  * Weight \\\u003C 52 kg\n  * History of previous CIN\n  * Immunocompromised patients","FEMALE","18 Years",{"count":135,"type":136},28,"ESTIMATED","INTERVENTIONAL",[139],"PHASE2","NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2\u002F3), to investigate if a course of treatment with oral artesunate can reverse pre-cancerous changes in the cervix and prevent the development and progression of invasive cancer. Findings from this study will increase our understanding of the effects of artesunate on CIN2\u002F3 and if confirmatory inform future clinical studies.",[142],"CIN 2\u002F3",[144,145,146,9,147],"CIN","HPV","drug repurposing","antimalarial","NOT_YET_RECRUITING","2025-07-23",{"date":151,"type":152},"2025-07-31","ACTUAL",{"date":154,"type":136},"2025-08-01",{"date":156,"type":136},"2028-06-30",{"name":5,"class":6},5]